The targeted inactivation of ALCAT1 prevents conditions like diet-induced obesity, non-alcoholic fatty liver disease (NAFLD), and MPTP-induced neurotoxicity, can ameliorate deficiency, and inhibits apoptosis [31,33,34]. Here, LCLAT1 is linked to obesity disorder.